Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Aspirin: A Novel Drug for Dental Decay

By Joanne Van Zuidam | September 11, 2017

“Take two aspirins and call me in the morning,” is no longer a mantra just for doctors. New research suggests that the drug may be a novel therapy for another group of practitioners: dentists.

A preventable disease, tooth decay affects billions worldwide. The condition results in cavities, nerve damage, pain and loss of tooth structure. Treatment involves fillings which, as many of us have experienced, may need to be replaced over the course of a lifetime.  

Now, new research from Queens University Belfast has revealed that aspirin could reverse the effects of tooth decay.

The researchers combined genomics and novel bioinformatics to identify aspirin as a candidate drug. It appears that aspirin’s properties stimulate existing stem cells in the tooth to promote regeneration of the damaged tooth structure.

According to a university statement, treatment of stem cells from teeth with low-dose aspirin significantly increased mineralization and the expression of genes responsible for forming dentine, the hard tooth structure that is usually damaged by decay. The researchers believe this novel discovery, coupled with the known anti-inflammatory and pain relieving effects of aspirin, could provide a unique solution for controlling tooth nerve inflammation and pain while promoting natural tooth repair.

“There is huge potential to change our approach to one of the biggest dental challenges we face,” said principal investigator El Karim. “Our initial research findings in the laboratory suggest that the use of aspirin, a drug already licensed for human use, could offer an immediate innovative solution enabling our teeth to repair themselves.”

The team’s next step is to develop an appropriate delivery system to test the drug efficacy in a clinical trial.

The findings were presented at the British society for Oral and Dental Research Annual Conference. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50